Abstract: Non-infectious uveitis (NIU) treatment is designed to control inflammation, reduce complications and protect vision. NIU intravitreal injection therapy can reduce systemic side effects and frequent drug use, and has become an effective alternative to systemic drug use. In addition, the intravitreal injection approach can achieve personalized and precise treatment for NIU patients. Intravitreal injection of glucocorticoid (Ozurdex, Retisert, Iluvien, Yutiq, triamcinolone acetonide), anti-vascular endothelial growth factor (bevacizumab, ranibizumab, aflibercept), anti-tumor necrosis factor-α (adalimumab, infliximab), immunosuppressants (sirolimus, methotrexate, cyclosporine A) can be effective treatment NIU inflammation and complications related to macular edema and inflammatory choroidal neovascularization. But the lack of controlled studies makes it difficult to compare these drugs, and some are expensive and have little experience in clinical trials. (Int Rev Ophthalmol, 2021, 45： 425-430)

Key words: non-infectious uveitis, intravitreous injection therapy